Pharmacy

Hello, Please provide any training materials held by the Trust that relate to withdrawing from, discontinuing or stopping psychiatric drugs. Psychiatric drugs include antidepressants, benzodiazepines, antipsychotics, mood stabilisers and stimulants. Please provide this information in relation to the last 12 months: 26/09/24 – 26/09/25 If you are unable to provide this information, please advise on how the request can be amended so that you are able to comply. Many thanks!

Dear Information Team

This is an information request relating to the cost of drugs going out of date.

Please include the following information, broken down by the following financial years: 2022-23, 2023-24, 2024-25

• What is the total value of drugs that have been disposed of due to going past their expiry date in each year

• The top five drugs disposed of in each year measured by the value of the drugs disposed

If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under the Section 16 obligations of the Act, as to how I can refine my request.
If you have any queries please don’t hesitate to contact me via email or phone and I will be very happy to clarify what I am asking for.

I would prefer a response via email, but if this is not possible, I will gladly accept letters to the address below.

Please acknowledge this information request as soon as possible.

Kind regards,

Please let me know the patient group directive or other means by which paramedics are allowed to dispense dexamethasone without medical / doctor input at community hospitals, particularly Cinderford Community Hospital. Thank you

FOI request for the following data for Gloucestershire Health and Care NHS Foundation Trust:

1. The number of unique patients with a recorded diagnosis of Primary Immunodeficiency (PID) in Q2’25(April, May, and June 2025)
a. Of these PID patients, what is the number of PID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025) If possible, segment patients by brand used e.g 5 patients on Cuvitru
b. How of these Ig treated PID patients are naïve (new starts) in Q2’25(April, May, and June 2025)?

2. The number of unique patients with a recorded diagnosis of Secondary Immunodeficiency (SID) in Q2’25(April, May, and June 2025)
a. Of these SID patients, what is the number of SID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used?
b. How of these Ig treated SID patients are naïve (new starts) in Q2’25(April, May, and June 2025)?

3. The number of unique patients with a recorded diagnosis of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Q2’25(April, May, and June 2025)
a. Of these SID patients, what is the number of CIDP patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used?
b. How of these Ig treated CIDP patients are naïve (new starts) in Q2’25(April, May, and June 2025)?

4. The number of immunoglobulin vials/volume in grams distributed to Gloucestershire Health and Care NHS Foundation Trust in each month for April, May, and June 2025, broken down by product (see below).

I would also like to request the number of patients Gloucestershire Health and Care NHS Foundation Trust by brand if available:

•Vigam
•Flebogamma DIF
•Gammaplex
•Gamunex-C
•Octagam
•Gamten
•Kiovig
•Intratect
•Privigen
•Iqymune
•Gammanorm
•Subcuvia
•Subgam
•Hizentra
•Hyqvia
•Cuvitru
•Panzyga
•Xembify
•Cutaquig
• Vyvgart (Efgartigimod)

Preferably I would like the data in .xlsx or .csv format. Alternatively a table will suffice
Thanks for your support.

Under the Freedom of Information Act 2000, I am requesting aggregate information regarding services provided or commissioned by your Trust in relation to peripheral neuropathic pain (PNP), with a specific focus on: – Post-surgical neuropathic pain (PSNP) – Cancer-related neuropathic pain (CRNP) – Painful diabetic peripheral neuropathy (PDPN) Please break down the information by individual service, clinic, and by hospital site. 1. Patient Numbers & Treatment Modalities (Last 12 Months) For each hospital site or service, please provide: The number of patients seen for each of the following conditions: – PSNP – CRNP (please split into surgically induced and chemotherapy-induced) – PDPN – Please also break this down by hospital department. Treatment Modalities For each hospital site or service, please indicate Yes or No as to whether the following treatment modalities are available for PNP. Where stated yes please provide patient numbers for the latest 12-month period. Gabapentin prescriptions Botulinum toxin (Botox) injections TENS (Transcutaneous Electrical Nerve Stimulation) Acupuncture (including PENS – Percutaneous Electrical Nerve Stimulation) Theatre-based nerve stimulation procedures (e.g., spinal cord stimulators or other implanted/surgical neuromodulation devices) If exact numbers are unavailable, proxy data is acceptable (e.g., the percentage of neuropathic pain patients receiving each treatment modality). 2. Service Provision Does your Trust or provider offer specific or dedicated services for PSNP, CRNP, and/or PDPN? – If yes, please list each relevant service or site (e.g., pain clinic, neurology clinic, diabetic foot clinic, community pain service) along with their addresses. For each listed site or service, please indicate: – The types of healthcare professionals routinely involved (e.g., pain specialists, neurologists, specialist nurses, physiotherapists, psychologists) – The number of staff per role (headcount or FTE if available) 3. Referral Pathways & Service Specifications Are there established care pathways, referral criteria, or service specifications for PSNP, CRNP, and/or PDPN? – If yes, please supply relevant documents or summaries. – If not, please clarify whether these conditions fall under broader chronic pain, MSK, diabetes, or oncology pathways. 4. Clinical Guidelines, Protocols, Strategic Plans Has the Trust developed or contributed to any strategic plans, business cases, or service specifications for PSNP, CRNP, or PDPN? – If so, please provide relevant documents, including any timelines and associated funding information. Are there any specific clinical guidelines, care pathways, or treatment protocols in use? For example: – NICE CG173 – NEUPSIG – Local pathways for diabetes- or oncology-related neuropathy – If yes, please provide copies or summaries of key components. 5. Funding & Budgets What was the total expenditure on neuropathic pain services in the most recent full financial year? – If no specific figure is available, please provide overall pain management funding and any known distribution (e.g., primary/community vs secondary care). – Please indicate the type of funding, e.g. tariff or block contract 6. Planned or Recent Service Changes Are there any recent, ongoing, or planned changes to: – Commissioning arrangements – Referral pathways – Service structure – Clinical treatment options for PSNP, CRNP, or PDPN? If yes, please provide details, including the relevant sites, timelines, and the rationale for these changes. 7. Data Format and Guidance Please provide all data in a machine-readable format (e.g., Excel or CSV). – If any part of the request is unclear or may exceed appropriate cost/time limits, please contact me to discuss refinement, in accordance with Section 16 of the FOI Act.

Under the Freedom of Information Act 2000, I would like to request the following information:

I would like to request the following information regarding MM, VIR & ID workload within the Trust.

The request is as follows:

1. Does your trust have dedicated virology laboratories, or are diagnostic tests for viral infections conducted in microbiology laboratories?

2. Do you provide clinical advice to more than 1 trust? If so, does that include onsite availability and how many trusts, hospitals, health boards, and organisations?

3. Is your trust responsible and/or do they cover any other laboratory, if so, how many laboratories?

4. What type of lab setup does your organisation currently use?

5. Approximately how many tests have you received yearly for swabs, blood, urine & stools in the last 5 years for MM, MVIR & ID?

6. As a medical microbiologist / medical virologist accredited in infectious diseases, do you provide inpatient care?

7. How many of your working hours are spent between the listed work areas, per week?

8. How many microbiologists also do virology workload

9. Does the service cover the listed out-of-hours (inpatient or other)

Under the Freedom of Information Act, please could I request the following information from your trust:

1. In your organisation, do you employ “job planning” for pharmacists (job planning in this instance is typically the division of a working week into half day “sessions” allocated to commitments such as clinical work, development, supporting professional activities time, teaching, research, etc)?

2. How many pharmacists do you employ? Please state headcount

3. Of the pharmacists that you employ, how many have job plans?

4a. For each pharmacist with a job plan, please provide the proportion of contracted hours allocated to protected* time for supporting professional activities (SPA), also known as protected learning time or professional development time

4b. For each pharmacist without a job plan, please provide the proportion of contracted hours allocated to protected time for supporting professional activities (SPA), also known as protected learning time or professional development time

5. If it is not possible to provide an answer to question 4a or 4b, please provide the recommended allocation to supporting professional activities (SPA), also known as protected learning time or professional development time, in hours per week for a full-time employed pharmacist.

*For the purposes of this FOI request, protected is defined as a time allocation that should be uninterrupted and dedicated to non-mandatory training and development, although this may not always be the case.

This is an information request relating to NHS Trusts buying and supplying Paracetamol and ibuprofen.

Please include the following information for the financial years 2022/23, 2023/24 and 2024/25:

• The total number of individual patients to whom paracetamol and ibuprofen were prescribed by your Trust annually.
• The total amount spent by your Trust on supplying prescribed paracetamol and Ibuprofen in each of those financial years.
• If available, a breakdown of the form in which paracetamol was prescribed (e.g., tablets, capsules, liquid suspension, etc.) and associated costs for each form.
• What are the specific conditions which qualify a patient to be prescribed paracetamol or ibuprofen? Or what is your general policy for qualifying a prescription for paracetamol or ibuprofen?

Please can you state if the Trust typically informs individual clinics regarding FOI requests made by the public. If this is not routine, please indicate circumstances when a clinician would be informed regarding a FOI request.

Did the hospital trust use high dose PPI medication, e.g. omeprazole to treat Eosinophilic Oesophagitis (EoE) in children before June 2018?
2. When did the use of high dose PPI become routine treatment for
EoE?